长沙晚报掌上长沙7月15日讯（全媒体记者 刘军）A股三大指数15日涨跌不一。截至收盘，沪指跌 0.42%，收报3505点；深证成指涨0.56%，收报10744.56点；创业板指涨1.73%，收报2235.05点。沪深两 市成交16121亿元，较15日放量1533亿元。 行业板块多数收跌，珠宝首饰、煤炭行业、电力行业、采掘行业、能源金属、光伏设备、农药兽药、酿 酒行业跌幅居前，互联网服务板块涨幅居前。个股方面，上涨股票1332只，涨停49只；下跌股票4017 只，跌停25只。 15日大盘在银行、地产等蓝筹股大跌的影响下，低开低走。沪指盘中跌破10日均线，最低回踩3483点附 近。虽然下午沪指逐步回升，但最终还是以下跌报收。15日大盘最大的特点就是让人看不懂：明明传来 了上半年GDP增速5.3%远超预期、英伟达恢复中国AI芯片销售的两大利好，大盘却上演跳水大戏，不 少股友大呼看不懂。"上半年经济数据向好，市场预期后续的刺激力度可能会减弱，所以一些资金开 始'抢跑'。"一位网友如是说。能够证明这一观点的是，主力资金在14日流出近400亿元后，15日再次大 幅流出超524亿元。 虽然大盘大跌，但15日A股市场也不乏亮 ...

Core Viewpoint - Nanjing New Pharmaceutical Co., Ltd. has announced multiple delays in its fundraising projects, particularly the "Marketing Channel Network Upgrade Project," which has been postponed to December 31, 2026, indicating ongoing challenges in project execution and market competition [1][3][4]. Group 1: Project Delays - The "Marketing Channel Network Upgrade Project" was initially set to be operational by June 30, 2025, but has now been delayed by an additional 18 months [1][3]. - The project aims to establish 8 new offices and upgrade 22 existing ones, with a total investment of 120 million yuan [2]. - The delays are attributed to macroeconomic conditions, industry policies, and a reduced need for new offices due to strategic adjustments [3][4]. Group 2: Termination of Projects - The company has terminated the "Palivizumab Dry Powder Inhalation Project" and redirected the remaining funds of 43.97 million yuan to the "Palivizumab Inhalation Solution Project" [4][5]. - The "Palivizumab Inhalation Solution Project" has also been delayed to December 31, 2026, with an increased funding allocation of 214 million yuan [4][6]. Group 3: Financial Performance - Nanjing New Pharmaceutical has faced significant financial challenges, with revenues declining from 1.03 billion yuan in 2020 to 263 million yuan in 2024, representing a decrease of over 70% [8]. - The company has reported net losses in all years since its IPO, except for the first year, with a net profit of 128 million yuan in 2020 turning into a loss of 357 million yuan in 2024 [8]. - In Q1 2025, the company reported a revenue drop of 70.21% year-on-year, primarily due to lower market demand for antiviral products and price reductions [8]. Group 4: Market Strategy - The company has adopted a price reduction strategy to maintain market share in the competitive antiviral market, with a 43.51% price cut on its core product, Palivizumab, in 2023 [7]. - Despite these efforts, the declining sales and increased competition have not improved the company's financial situation [7][8].